Search results
Results from the WOW.Com Content Network
[1] Formulation studies then consider such factors as particle size, polymorphism, pH, and solubility, as all of these can influence bioavailability and hence the activity of a drug. The drug must be combined with inactive ingredients by a method that ensures that the quantity of drug present is consistent in each dosage unit e.g. each tablet ...
Drug permeability, together with drug aqueous solubility are the two parameters that define the fate of the active ingredient after oral administration and ultimately define its bioavailability. [1] When drug permeability is empirically measured in vitro , it is generally called apparent permeability (P app ) as its absolute value varies ...
Galenic formulation deals with the principles of preparing and compounding medicines in order to optimize their absorption.Galenic formulation is named after Claudius Galen, a 2nd Century AD Greek physician, who codified the preparation of drugs using multiple ingredients.
Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use.
Intravascular administration does not involve absorption, and there is no loss of drug. [4] The fastest route of absorption is inhalation. [5] Absorption is a primary focus in drug development and medicinal chemistry, since a drug must be absorbed before any medicinal effects can take place. Moreover, the drug's pharmacokinetic profile can be ...
A drug carrier or drug vehicle is a substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. [1] Drug carriers are primarily used to control the release of drugs into systemic circulation.
The Theory and Practice of Industrial Pharmacy (Third ed.). Lea & Febiger, Philadelphia. ISBN 0-8121-0977-5. US Patent 8728521, Hemant N. Joshi, issued May 20, 2014 US Patent 9884024, Hemant N. Joshi, issued February 6, 2018 US Patent 10357461, Hemant N. Joshi, issued July 23, 2019 Sant, Harshada (April 2018).
125 I is a gamma emitter with a long half-life of 59.4 days (the longest of all radioiodines used in medicine). Iodine-123 is preferred for imaging, so I-125 is used diagnostically only when the test requires a longer period to prepare the radiopharmaceutical and trace it, such as a fibrinogen scan to diagnose clotting.